CytomX Therapeutics, Inc.
Here’s whether CytomX Therapeutics, Inc. (CTMX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 59 — healthy momentum range; strong 1-year return of +665.4%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-4.96% over 10 days); 3-month momentum negative (-10.6%); declining volume on rally — weak conviction (0.48x 30d avg). Currently 41.3% off its 52-week high. Score: +0/7.
CTMX is holding above its long-term 200-day MA ($3.74) but has slipped below the 50-day MA ($4.95), pointing to short-term weakness in an otherwise intact trend. An RSI of 59.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +665.4% compares to +35.1% for SPY (beat the market by 630.4%). The current 41.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.